GeoVax Labs, which is seeking to develop a vaccine to combat AIDS, is receiving a $15 million boost.
The National Institutes of Health will pour the millions into GeoVax research through a grant for integrated preclinical and clinical trial research.
GeoVax (Nasdaq: GOVX) noted that grants are awarded on a “competitive basis.” The funds will be used for vaccine development, production, and human clinical trials. Phase II clinical trials are planned for next year.
“This grant will allow GeoVax to move forward our AIDS vaccine evaluation program more efficiently and more rapidly,” said Harriet Robinson, chief scientific advisor for GeoVax.
